B7-H3.CAR-28z-Ts

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameB7-H3.CAR-28z-Ts
Drug Alias NameB7-H3.CAR-BBz-Tsanti-B7-H3 CAR T-cell therapy (University of North Carolina/Harvard Medical School)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD276 antigen modulators
TargetsCD276 antigen
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina, Greensboro
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of North Carolina, GreensboroHarvard Medical School
Active IndicationsN/A
Inactive IndicationsCarcinoma, Pancreatic Ductal

Other Information

ATC CodeN/A
Related LinksN/A